interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription

Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.

None of the approved immunomodulatory drugs in adults Multiple Sclerosis (MS) patients have been officially approved for the pediatric patients and are currently used off-label in this population. In this study, we evaluated the effectiveness and tolerability of intramuscular interferon beta1-a (Avonex(®)) and subcutaneously injected interferon beta1-b (Betaferon(®)) in children with definite r...

P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial

Background: High dose Interferon Beta and Fingolimod are efficient in Multiple Sclerosis. Objectives: Comparison the efficacy of these two drugs in patients with treatment failure on low dose interferon beta. Materials and Methods: The MS patients (McDonald criteria 2010) with the history of unbeneficial treatment on low dose interferon beta participated in this randomized clinical trial ...

Interferon beta and suicide in multiple sclerosis.

Inhibitory effect of the interferon-beta on the release of endothelial cell derived microparticles in patients with multiple sclerosis

Abstract Introduction: Increased levels of microparticles (MPs) have been reported in many autoimmune diseases such as multiple sclerosis (MS). In MS, endothelial cells release MPs from their membranes following the activation of lymphocytes and the production of inflammatory cytokines. The aim of this study was to investigate the inhibitory effect of interferon beta (INFβ) on the release of en...

Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis.

BACKGROUND Currently available disease-modifying therapies (DMTs) are known to be only partially effective in adults with multiple sclerosis (MS). Little is known about pediatric patients with MS who experience refractory disease while receiving first-line DMTs. OBJECTIVE To assess the occurrence and management of refractory disease in a group of pediatric patients with MS treated with first-...